Gammagard is a well-established intravenous immunoglobulin (IVIG) medication that has been prescribed for the treatment of primary immunodeficiency (PI) and multifocal motor neuropathy (MMN) for over 15 years. It is available in a ready-to-use liquid form and can be administered intravenously or subcutaneously. Gammagard is known for its unique formula, which does not contain added sugars, sodium, preservatives, or proline stabilizers, making it a suitable option for individuals with specific dietary restrictions. The medication is also stabilized and buffered with glycine, ensuring its safety and efficacy.
Gammagard is accompanied by important safety information, as it can cause severe allergic reactions, decreased kidney function or failure, and blood clots in various parts of the body. It is not recommended for individuals who have had a severe allergic reaction to immune globulin or other blood products, or those with selective or severe immunoglobulin A (IgA) deficiency. Additionally, Gammagard may affect the effectiveness of certain vaccines, and pregnant or nursing individuals should consult with their healthcare provider before using the medication. Common side effects include mild to moderate pain, swelling, itching, redness, and bruising at the infusion site.
Generated from the website